Sp132
PERSONALIZED NUTRITION: ARE WE READY FOR PRIME TIME
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
The literature in personalized nutrition in healthcare has been expanding. This program will review the scientific principles of nutritional genomics and metabalomics in predicting and impacting health and disease. The role of circadian rhythm physiology in disease and its role in guiding dietary to impact the gut microbiome-immune axis in health and potentially disease-will also be discussed.
The literature in personalized nutrition in healthcare has been expanding. This program will review the scientific principles of nutritional genomics and metabalomics in predicting and impacting health and disease. The role of circadian rhythm physiology in disease and its role in guiding dietary to impact the gut microbiome-immune axis in health and potentially disease-will also be discussed.
Presenter
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Q&A PANEL DISCUSSION
The literature in personalized nutrition in healthcare has been expanding. This program will review the scientific principles of nutritional genomics and metabalomics in predicting and impacting health and disease…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
